Cancer Rop Co. Ltd. (180400) - Total Liabilities
Based on the latest financial reports, Cancer Rop Co. Ltd. (180400) has total liabilities worth ₩24.60 Billion KRW (≈ $16.67 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 180400 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cancer Rop Co. Ltd. - Total Liabilities Trend (2014–2025)
This chart illustrates how Cancer Rop Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Cancer Rop Co. Ltd..
Cancer Rop Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Cancer Rop Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zumtobel Group AG
VI:ZAG
|
Austria | €575.33 Million |
|
UniTest Incorporation
KQ:086390
|
Korea | ₩79.12 Billion |
|
Thong Guan Industries Bhd
KLSE:7034
|
Malaysia | RM479.51 Million |
|
Multi Spunindo Jaya Tbk.
JK:MSJA
|
Indonesia | Rp25.54 Million |
|
Nnit AS
CO:NNIT
|
Denmark | Dkr731.00 Million |
|
Tianjin Capital Environmental Protection Group Company Limited
F:TIA
|
Germany | €14.34 Billion |
|
AGV Products Corp
TW:1217
|
Taiwan | NT$7.35 Billion |
|
Airtel Africa Plc
LSE:AAF
|
UK | GBX10.23 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Cancer Rop Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Cancer Rop Co. Ltd.'s balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cancer Rop Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cancer Rop Co. Ltd. (2014–2025)
The table below shows the annual total liabilities of Cancer Rop Co. Ltd. from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩59.11 Billion ≈ $40.06 Million |
+5.54% |
| 2024-12-31 | ₩56.00 Billion ≈ $37.95 Million |
-21.28% |
| 2023-12-31 | ₩71.14 Billion ≈ $48.21 Million |
+37.87% |
| 2022-12-31 | ₩51.60 Billion ≈ $34.97 Million |
+58.10% |
| 2018-12-31 | ₩32.64 Billion ≈ $22.12 Million |
+45.15% |
| 2017-12-31 | ₩22.49 Billion ≈ $15.24 Million |
+3388.71% |
| 2016-12-31 | ₩644.52 Million ≈ $436.78K |
+4.83% |
| 2015-12-31 | ₩614.80 Million ≈ $416.64K |
+17.58% |
| 2014-12-31 | ₩522.87 Million ≈ $354.34K |
-- |
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more